Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Drug news & perspectives - 1 Dec 2009

Diamond Jennifer R, Borges Virginia F, Eckhardt S Gail, Jimeno Antonio

Abstract excerpt

BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 20140280
DOI: 10.1358/dnp.2009.22.10.1440985

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20140280-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA in breast cancer: from risk assessment to therapeutic prediction.PMID 20140280Read ↗

Breast Cancer Predisposition Genes and Synthetic Lethality.Semantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsideSemantic proximity Read ↗

Targeting the BRCA1/2 Tumor SuppressorsSemantic proximity Read ↗

Cancer treatment according to BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

BRCA1/2 testing: therapeutic implications for breast cancer managementSemantic proximity Read ↗

New Therapeutic Options for BRCA Mutant PatientsSemantic proximity Read ↗

Crosstalk of DNA double‐strand break repair pathways in poly(ADP‐ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2‐mutated cancerSemantic proximity Read ↗

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?Semantic proximity Read ↗

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and BeyondSemantic proximity Read ↗

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Semantic proximity Read ↗

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.